Polyrizon (PLRZ) Total Liabilities (2023 - 2025)
Polyrizon's (PLRZ) quarterly Total Liabilities came in at $21.4 million in Q4 2025, up 286.46% YoY from $5.5 million in Q4 2024, and up 14.4% on a QoQ basis from $18.7 million in Q2 2025.
Polyrizon (PLRZ) Total Liabilities (2023 - 2025) Analysis & Trends
Polyrizon (PLRZ) has 3 years of Total Liabilities data on file, last reported at $21.4 million in Q4 2025.
- Quarterly Total Liabilities rose 286.46% year-over-year to $21.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $21.4 million (up 286.46% YoY) and the FY2025 annual result came in at $21.4 million, up 286.46% from the prior year.
- Total Liabilities climbed to $21.4 million in Q4 2025, from $18.7 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $21.4 million in Q4 2025 to a low of $559000.0 in Q4 2023.
- A 3-year average of $11.6 million and a median of $12.1 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2024 — Total Liabilities surged 892.31% — and 2025, when it soared 286.46%.
- Tracing PLRZ's Total Liabilities over 3 years: stood at $559000.0 in 2023, then surged by 892.31% to $5.5 million in 2024, then soared by 286.46% to $21.4 million in 2025.
- The last three Total Liabilities figures came in at $21.4 million (Q4 2025), $18.7 million (Q2 2025), and $5.5 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Polyrizon | 7.27 Mn | -4.22 Mn | - | 21.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 21.44 Mn |
| Jun 30, 2025 | 18.74 Mn |
| Dec 31, 2024 | 5.55 Mn |
| Dec 31, 2023 | 559,000.00 |